115 results about "Reabsorption" patented technology

The invention discloses a backlight module of a display device and a white light LED. The backlight module comprises a lamp bar and a light guide plate, wherein the lamp bar is provided with a plurality of ultraviolet light LEDs, and the light-entering face of the light guide plate and the ultraviolet light LEDs are arranged oppositely. A path of the process from light emitted by the ultraviolet light LEDs to the light shot from the light-exiting face of the light guide plate at least comprises an RGB quantum dot fluorescent powder layer. The RGB quantum dot fluorescent powder layer comprises a red light quantum dot fluorescent screen, a green light quantum dot fluorescent screen and a blue light quantum dot fluorescent screen, wherein the red light quantum dot fluorescent screen, the green light quantum dot fluorescent screen and the blue light quantum dot fluorescent screen are sequentially arranged. The RGB quantum dot fluorescent powder layer generates high-purity white light under excitation of ultraviolet light emitted by the ultraviolet light LEDs. As the RGB quantum dot fluorescent powder layer is formed by sequentially arranging the red light quantum dot fluorescent screen, the green light quantum dot fluorescent screen and the blue light quantum dot fluorescent screen, color saturation of the backlight module is improved, and the problem of reabsorption of RGB quantum dot fluorescent powder is solved.

Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are adrenergic receptor α2B antagonists. The compounds may also bind to and antagonize adrenergic receptor α2B. The compounds may find use in therapy, e.g., to (i) reduce blood pressure and / or (ii) promote renal blood flow and / or (iii) decrease or inhibit sodium reabsorption. The compounds may also be used to treat diseases or conditions that are, or are expected to be, responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular and renal disorders is particularly described.

Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are adrenergic receptor α2B antagonists. The compounds may also bind to and antagonize adrenergic receptor α1B—The compounds may find use in therapy, e.g., to (i) reduce blood pressure and / or (ii) promote renal blood flow and / or (iii) decrease or inhibit sodium reabsorption. The compounds may also be used to treat diseases or conditions that are, or are expected to be, responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular and renal disorders is particularly described.

This disclosure is directed to pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and / or a neuronal disorder. The compounds may bind to and antagonize receptor α2B, α1B or α2A. The compounds may find use in therapy, e.g., to (i) reduce blood pressure and / or (ii) promote renal blood flow and / or (iii) decrease or inhibit sodium reabsorption, or to regulate blood glucose level, increase insulin secretion and treat diseases or conditions that are, or are expected to be, responsive to an increase in insulin production. The compounds may also be used to treat diseases or conditions that are expected to be responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular, renal disorders or type 2 diabetes is particularly described.

The present invention provides novel type IIc Na / Pi cotransporters. These cotransporters are important Pi transporters that are highly expressed during the growth period from the weaning stage to the adult stage. Furthermore, the present invention provides FGF23 and mutants thereof as factors that regulate the expression of type II Na / Pi cotransporters. FGF23 suppresses Pi reabsorption through suppression of type II Na / Pi cotransporter expression in kidneys. Therefore, FGF23 can be used as a target substance for regulating Pi reabsorption in kidneys. The present invention provides important factors for the development of preventive and therapeutic agents for hyperphosphatemia or hypophosphatemia.

An article of manufacture and method for making a luminescent solar concentrator or a wavelength shifting device. The article includes a light guide or optical medium with a luminescent material disposed therein or deposited on the surface. The luminescent material is formulated to absorb incoming radiation and wavelength shift that radiation to a larger wavelength for processing and use, and to minimize reabsorption of the shifted radiation by the luminescent material.

Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are adrenergic receptor α2B antagonists. The compounds may also bind to and antagonize adrenergic receptor α1B. The compounds may find use in therapy, e.g., to (i) reduce blood pressure and / or (ii) promote renal blood flow and / or (iii) decrease or inhibit sodium reabsorption. The compounds may also be used to treat diseases or conditions that are, or are expected to be, responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular and renal disorders is particularly described.

The invention belongs to the field of refinery saturated resource utilization, and relates to a separation system of saturated hydrocarbon cracking gas and a utilization method of rich ethane / a propane saturated hydrocarbon. The separation system of the saturated hydrocarbon cracking gas includes a cracking furnace, a waste heat boiler, a quenching water tower, a compressor, an absorption tower, adesorption tower, a reabsorption tower, a drying tower, a deethanization tower, a carbazide hydrogenation reactor and an ethylene rectifying tower, wherein the cracking furnace is connected successively with the waste heat boiler, the quenching water tower and the compressor and then connected with the absorption tower, the tower top of the absorption tower is connected with the reabsorption tower, and the tower kettle of the absorption tower is connected with the desorption tower; the tower top of the desorption tower is connected with the drying tower and then connected with the deethanization tower, and the tower kettle of the desorption tower is connected with the top of the absorption tower; the tower top of the deethanization tower is connected successively with the carbazide hydrogenation reactor and the ethylene rectifying tower; and the tower top of the ethylene rectifying tower is connected with the compressor, the tower kettle of the ethylene rectifying tower is connected with the cracking furnace, and the side part of the ethylene rectifying tower is connected with the production line of polymer grade ethylene products. According to the separation system of the saturated hydrocarbon cracking gas and the utilization method of the rich ethane / the propane saturated hydrocarbon, investment is low, energy consumption is low, the process is simple, and the investment recovery rate is high.

The present invention is comprised within tissue engineering and, specifically, within bone regeneration. The invention relates to a porous three-dimensional matrix of monetite which is biocompatible, has structured porosity and is predefined and reabsorbable, as well as to the method of synthesis capable of producing said material and the applications thereof. These matrices are a perfect base for cell colonization and proliferation, allowing the application thereof in tissue engineering and bone regeneration as a result of their advantageous properties of biocompatibility, reabsorption, osteoinduction, revascularization, etc.

The invention relates to vortioxetine hydrobromide and in particular relates to a crystal of 1-[2-(2,4-dimethylphenylthioxo)phenyl] piperazine hydrobromide. The crystal uses Cu-K alpha radiation. In a powder X-ray diffraction pattern shown by a 2theta angle, diffraction peaks exist at about 6.89 degrees, 9.73 degrees, 13.78 degrees and 14.62 degrees. The invention also relates to a preparation method of the crystal and a drug composition containing the compound. The compound shows the serotonin reabsorption inhibitory activity, has activities towards a serotonin receptor 1A (5-HT1A) and a serotonin receptor 3 (5-HT3), can be used for treating CNS (central nervous system)-related diseases, in particular can be used for treating depressive disorder, especially major depressive disorder of adults, and can be also used for treating other CNS-related diseases.

The present invention generally relates to improved bioartificial kidneys (BAKs), and in certain embodiments to improved bioartificial kidneys that are portable and / or wearable by a user. In some embodiments, the BAKs may comprise an ultrafiltration unit and a reabsorption unit. The reabsorption unit may contain a reabsorption membrane having a layer of renal proximal tubule cells disposed thereon, where the renal proximal tubule cells selectively allow solutes to pass through the reabsorption membrane. In some embodiments, at least the reabsorption unit may be configured as a substantially flat-plate filtration device, which can impart advantageous properties such as improved maintenance of the renal proximal tubule cell layer, more facile monitoring of the renal proximal tubule cell layer as well as enhanced profile for wearability.

The invention discloses a brown coal low temperature carbonization method. The method comprises the following steps of: by a gas heat carrier, firstly, heating the coal under the condition of isolating air, removing more than 90% of total moisture, crystal water and partial oxygen-containing functional groups which have influence on the coal heat value, and enriching the coal heating constituents; and further heating the coal to form solid semicoke, purifying the separated volatile constituent substance to recycle coal tar and coal gas products, recycling the afterheat of the high temperature semicoke and cooling the semicoke to collect the semicoke. The obtained semicoke has the advantages of high heat value, excellent stability and non-reabsorption and the like. The method is simple in technology, low in energy consumption, pollution-free and high in product quality, capable of realizing industrial large-scale production, and easy to generalize widely.

The invention provides a composition of plant extract and a method for regulating and controlling blood sugar by using the same. The composition of a plant extract comprises a glycosidase inhibitor used for blocking digestion and absorption of sugar by organism, and a sodium glucose transporter inhibitor used for inhibiting sodium glucose transporter so as to inhibit the reabsorption of the glucose by kidney. The glycosidase inhibitor comprises L-arabinose, 1-deoxynojirimycin, phaseolin or chlorogenic acid; the sodium glucose transporter inhibitor is extracted from phlorizin; the phlorizin is extracted from lithocarpus polysachyus rehd, branches or leaves of a fruit tree. On the one hand, the composition provided by the invention can be used for blocking excessive absorption of the sugar, on the other hand, the composition can be used for inhibiting the sodium glucose transporter in the kidney to control the reabsorption of the glucose so as to ultimately lower blood sugar and balance the blood glucose level within the scope of health.

A method of hydrating nasal airway surfaces in a subject in need of such treatment comprises topically applying a sodium channel blocker to a nasal airway surface of the subject in an amount effective to inhibit the reabsorption of water by the surface. The channel blocker may be a pyrazinoylguanidine sodium channel blocker, such as benzamil, phenamil, amiloride, or a pharmaceutically acceptable salts thereof. The method may further comprise the step of topically applying a P2Y2 receptor agonist to a nasal airway surface of the subject in an amount effective to stimulate chloride secretion by the nasal airway surface. In a preferred embodiment, the sodium channel blocker is a covalent conjugate of a pyrazinoylguanidine sodium channel blocker and a non-absorbable carrier moiety (e.g., albumin, polyethylene glycol). Such compounds may also be administered to other mucosal surfaces where it is desired to inhibit the reabsorption of water.

This disclosure is directed to pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and / or a neuronal disorder. The compounds may bind to and antagonize receptor α2B, α1B orα2A. The compounds may find use in therapy, e.g., to (i) reduce blood pressure and / or (ii) promote renal blood flow and / or (iii) decrease or inhibit sodium reabsorption, or to regulate blood glucose level, increase insulin secretion and treat diseases or conditions that are, or are expected to be, responsive to an increase in insulin production. The compounds may also be used to treat diseases or conditions that are expected to be responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular, renal disorders or type 2 diabetes is particularly described.

In one embodiment, the transparent growth substrate (38) of an LED die is formed to have light scattering areas (40A-C), such as voids formed by a laser. In another embodiment, the growth substrate is removed and replaced by another substrate that is formed with light scattering areas. In one embodiment, the light scattering areas are formed over the light absorbing areas of the LED die, to reduce the amount of incident light on those absorbing areas, and over the sides (42A, 42B) of the substrate to reduce light guiding. Another embodiment comprises a replacement substrate may be formed to include reflective particles in selected areas where there are no corresponding light generating areas in the LED semiconductor layers such as -type metal contacts (28). This prevents reabsorption into absorbing regions of the semiconductor layer thereby enhancing external efficiency of the device. A 3D structure may be formed by stacking substrate layers containing the reflective areas. The substrate may be a transparent substrate or a phosphor tile (20) that is affixed to the top of the LED.

Hydrogenated pyrido[4,3-b]indoles and pyrido[3,4-b]indoles are described. The compounds may bind to and are adrenergic receptor α2B antagonists. The compounds may also bind to and antagonize adrenergic receptor α1B. in The compounds may find use in therapy, e.g., to (i) reduce blood pressure and / or (ii) promote renal blood flow and / or (iii) decrease or inhibit sodium reabsorption. The compounds may also be used to treat diseases or conditions that are, or are expected to be, responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular and renal disorders is particularly described.

A printed circuit board (PCB) having an individual reflective structure and a method for manufacturing a light emitting diode (LED) package using the same, which can prevent reabsorption of light between LED chips by providing an individual reflective structure between the LED chips when the LED package is configured using two or more LED chips. The PCB includes a PCB; a wiring pattern-forming material layer formed on the PCB with an insulating layer interposed therebetween; dams formed on the wiring pattern-forming layer around chip mounting areas of the PCB; and a light reabsorption prevention dam formed on the wiring pattern-forming material layer between the chip mounting areas where LED chips are mounted.

The invention is in the field of nanostructure synthesis. Provided are highly luminescent nanostructures, particularly highly luminescent quantum dots, comprising a nanocrystal core and a thin inner shell layer. The nanostructures may have an additional outer shell layer. Also provided are methods of preparing the nanostructures, films comprising the nanostructures, and devices comprising the nanostructures.

The invention relates to a device and method for preparing sulfite, belonging to the field of chemical industry. The method comprises the following steps of preparation of main absorption liquid, preparation of auxiliary absorption liquid, generation of intermediate slurry, reabsorption of residual SO2 gas, generation of a target product, separation of the target product, drying and packaging. In the production process of conventional sodium pyrosulfite or sodium sulfite, SO2 and sodium carbonate react in three-stage bubbling reaction kettles which are cascaded with each other. The power consumption of a unit product is as high as 235-280KWh; in the process of the application (the preparation of the sodium pyrosulfite or sodium sulfate), only a one-stage bubbling reaction kettle is used, the loss of pressure of gas is small, the energy consumption is low, and in general, the power consumption of the unit product is 135-160KWh.

Combination therapy comprising RXR modulators and glucose reabsorption inhibitors useful for the treatment of diabetes and Syndrome X are disclosed.

The present invention relates to an ophthalmic solution for the clarification of vitreous hemorrhages. More specifically, it relates to a pharmaceutically acceptable intraocular injectable solution, for the treatment of vitreous hemorrhages, whereby the reabsorption of such hemorrhage is encouraged. It enables the clarification of the vitreous hemorrhage in a significantly short period of time to allow for the timely diagnosis of the lesion and the repair of the damage the hemorrhage has caused to the vitreous body. The ophthalmic solution of the present invention is injected at least once into the vitreous humor of the patient in a therapeutically effective dose to obtain the desired result.

A release of the frozen solvent trapped inside a solidified gel occurs when the temperature increases, followed by a dissolving of a reactive substance present in a membrane that is located in direct physical contact with the gel, resulting in the reabsorption of the reactive substance dissolved in the solvent into the solid gel layer within a constant time. In this manner, the components generating color change come together within the solid gel layer initiating a reaction to change the color of the indicator layer. Thus, the increase in temperature above a melting point of the solid gel layer is enough to activate the intelligent label with an irreversible color change.

The invention discloses an Sr and Mg doped amorphous apatite material and crystalline apatite material, belonging to the field of biomedical materials. The different concentrations of Sr and Mg doped amorphous apatite material is rapidly prepared by using Ca(NO3)2, Mg(NO3)2, Sr(NO3)2, (NH4)2HPO4 and ammonia-water as raw materials and then is transformed to the different concentrations of Sr and Mg doped nano calcium-deficient hydroxyapatite or nano tricalcium phosphate material through heat treatment. Compared with traditional hydroxyapatite crystalline materials, the amorphous material has higher solubility. The amorphous apatite material and the crystalline apatite material have the beneficial effects that after Sr and Mg doping, Sr can achieve the effects of promoting new bone formation, reducing reabsorption of bone, adjusting calcium metabolism and reducing the activity of osteoclast, and Mg can achieve the effects of affecting early growth of bone substances and regulating growth and remodelling of the bone substances; therefore the synthesized amorphous apatite and the crystallized product thereof have important roles in the fields of bone repair and bone transplantation.

Glaucoma treatment devices are disclosed. In various example, the glaucoma treatment devices include multiple microporous layers arranged together to form a microporous body configured to help facilitate evacuation of fluid from a fluid-filled body cavity, and reabsorption of the evacuated aqueous humor by the body through tissue surrounding the glaucoma treatment device. In some examples, the glaucoma treatment device includes one or more portions configured to resist cellular ingrowth, and one or more portions configured to permit cellular ingrowth.

The invention relates to a preparation method for infant composite protein nutrition powder, which includes steps of (1) weighing lactalbumin powder, xanthan gum, calcium lactate, oligosaccharide and homogenized lecithin according to weight percent and mixing; (2) adding isoflavones and uniformly mixing; (3) sterilizing, aseptic packaging, subpackaging, inspecting and warehousing finished product. The added oligosaccharide of the present invention can adjust normal flora in body gastrointestinal tract, generates special enzyme serious, increases absorption and reabsorption of isoflavones, is rich in nutrients such as vitamin and trace elements, is especially favourable to growth of infant and is a nutrient milk capable of substituting breast milk. The method is easy, raw material source is wide and cost is low.

The invention provides a carbon dioxide capture system. The carbon dioxide capture system comprises an air blower, an absorption tower, a rich solution pump, a first heat pump system, a second heat pump system, a lean and rich solution heat exchanger, a desorption tower, a reboiler, a carbon dioxide cooler, a gas-liquid separator, a lean solution pump and a lean solution cooler. According to the carbon dioxide capture system provided by the invention, based on the arrangement of the air blower, the absorption tower, the rich solution pump, the first heat pump system, the second heat pump system, the lean and rich solution heat exchanger, the desorption tower, the reboiler, the carbon dioxide cooler, the gas-liquid separator, the lean solution pump and the lean solution cooler, through the repeated heat exchange of the first heat pump system, the second heat pump system and the lean and rich solution heat exchanger, idle residual heat inside the carbon dioxide capture system can be effectively and adequately utilized, the energy loss of the carbon dioxide capture system is lowered, and the energy utilization ratio of the carbon dioxide capture system, the desorption capacity of a rich solution, the reabsorption capacity of a lean solution and the purity of capture of carbon dioxide are improved.

The invention relates to a two-stage low temperature gasification device based on low-order fuel autocatalysis, and a two-stage low temperature gasification method based on low-order fuel autocatalysis, belonging to the field of clean energy utilization of low-order fuel. A pyrolysis reactor is communicated with a fluidized-bed gasifier and a cyclone separator, and the cyclone separator is sequentially communicated with a primary back feeding pipe, a spiral back feeder, a secondary back feeding pipe and the pyrolysis reactor. A moving bed pyrolysis system is replenished with non-carrier gas, high alkaline metal low-order fuel and alkaline earth metal low-order fuel are pyrolyzed by being heated together with a heat carrier in a mixing way, and part of pyrolysis products are gasified and reformed; the pyrolysis products are directly conveyed into a fluidized-bed gasifying system so as to be subjected to in situ low temperature gasification, and most coke and all tar are involved in the reaction; the heat carrier at an outlet of the fluidized-bed gasifying system is separated from synthesis gas by means of a cyclone separation system, the heat carrier enters to the moving bed pyrolysis system, and the synthesis gas discharged outside. The device and the method which are provided by the invention utilize pyrolysis coke to carry out in situ catalytic pyrolysis on part of tar and utilize reabsorption alkali metal and alkali earth metal to catalyze coke gasification at low temperature, thus realizing high efficient low temperature autocatalytic gasification of the low-order fuel.

The invention relates to the technical field of microfluidics and provides a microfluidic chip and an application thereof. The microfluidic chip comprises an upper substrate, a lower substrate, a first porous membrane and a second porous membrane, wherein a first liquid inlet, a second liquid inlet, a first liquid outlet, a second liquid outlet, a first chamber, a second chamber and a first microchannel are arranged on the upper substrate; the second liquid inlet, the first chamber, the second chamber and the second liquid outlet are sequentially communicated through the first microchannel; the lower substrate is provided with a third liquid inlet, a third liquid outlet, a third chamber, a fourth chamber and a second microchannel, and the third liquid inlet, the third chamber, the fourth chamber and the third liquid outlet are sequentially communicated through a second microchannel. According to the microfluidic chip, the four chambers are formed, upper fluid and lower fluid can be subjected to material exchange twice on porous membranes separating the four chambers, so that the blood purification process of glomerular filtration and tubular secretion and reabsorption of renal units can be simulated with high simulation degree.